Contents

Issue 138 • January 2024

In association with

Cover Story

Pharma’s path to Net Zero: Targeting Scope 3 emissions

Comment

VPAS is dead, long live VPAG

Interview

European Pharma legislation: hindrance or help?

In Depth

Pharma’s path to Net Zero: Targeting Scope 3 emissions

Profit vs inquiry: Clash of objectives in academic and commercial trials

CTO Europe 2023: A snapshot of challenges and opportunities in oncology

The future of cell and gene therapy manufacturing

VPAS is dead, long live VPAG

European Pharmaceutical legislation: hindrance or help?

Briefing

News in Numbers

Latest News

Latest Deals

Project Updates

In Data

M&A activity in the mining industry

Hiring activity in the mining industry decreased

Patent activity in the mining industry decreased

Sentiment in the mining industry increased

Yearbook

Pharma’s year end review for 2023

02/23/2024 23:27:04
  • Home | Pharma’s path to Net Zero: Targeting Scope 3 emissions
  • Editor's letter
  • Contents
  • Mimotopes Company Insight
  • Mimotopes
  • Briefing
  • News in Numbers
  • Latest News
  • Latest Deals
  • Project Updates
  • Dycem
  • In Depth
  • Pharma’s path to Net Zero: Targeting Scope 3 emissions
  • Profit vs inquiry: Clash of objectives in academic and commercial trials
  • CTO Europe 2023: A snapshot of challenges and opportunities in oncology
  • The future of cell and gene therapy manufacturing
  • VPAS is dead, long live VPAG
  • Q&A: European Pharmaceutical legislation: hindrance or help?
  • Natoli
  • Nipro
  • Yearbook
  • Yearbook contents
  • UK’s pharma regulatory scene reckons with changes in 2023
  • Pharma breakthroughs: 10 novel drug approvals that made headlines in 2023
  • Top themes of 2023: AI, precision medicine, virtual care, digital therapeutics
  • Humira biosimilars set the stage for long-awaited 2023 US launches
  • Inside the hunt for an Alzheimer’s disease vaccine
  • Pathbreakers: The journey of first generics
  • NASH drugs race to cross the finish line
  • Fighting AMR with a value and subscription model
  • Cancer treatment uncertainty: European nations struggle with drug shortages
  • Why are haemophilia gene therapies so expensive?
  • Top themes for the healthcare sector in 2024
  • Listings
  • Events
  • The top 100 most innovative companies in the US in 2023
  • Buyer's Guides
  • Next issue
12/18/2023 00:00:00